▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

XMFEBCapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

market crash GettyImages-499578669

Nov 15, 2017 by Todd Campbell

Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks

Worry about whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.

hired shaking handsGettyImages-478318398

Nov 14, 2017 by Todd Campbell

Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer

The global pharmaceutical giant has signed a deal that could be worth more than $1.5 billion to this clinical-stage cancer drug developer.

Nov 14, 2017 by Todd Campbell

Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today

The company's making inroads with its first commercial-stage drug, but expenses could present big headwinds.

Man pointing at dollar sign GettyImages-473559372

Nov 13, 2017 by Todd Campbell

Why Nektar Therapeutics Shares Are Rallying 13.8% Today

Encouraging results for one of its drugs in solid tumor cancers are sparking interest in the clinical-stage company.

man with new idea GettyImages-469000144

Nov 13, 2017 by Todd Campbell, Sean Williams, and Brian Feroldi

3 Top Healthcare Stocks to Buy in November

Healthcare stocks are some of the most intriguing long-term stocks to buy. Picking up these stars now could end up being very profit-friendly.

offshore rigs GettyImages-515446082

Nov 13, 2017 by Todd Campbell

Is It Time to Buy These Offshore Oil and Gas Drilling Stocks?

Rising crude oil prices and falling offshore development costs could help this struggling industry recover.

marijuana-on-top-of-money-getty_large

Nov 11, 2017 by Todd Campbell

Marijuana Stock Investing Goes "Big Time"

A big-money investment in marijuana hints at the money-making potential of this emerging industry.

rocket ship GettyImages-515682468

Nov 10, 2017 by Todd Campbell

This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today

This company took important steps forward last quarter to continue growing.

lab scientists 2 GettyImages-506712124

Nov 10, 2017 by Todd Campbell

Is This a Top Life Sciences Stock to Buy on Sale?

The life sciences industry is growing quickly and that may lead to market-beating returns for this company.

alrm2

Nov 10, 2017 by Todd Campbell

Is This a Top Internet of Things Stock to Buy?

This fast-growing company is already profiting from the growing adoption of Internet of Things.

numbers GettyImages-497569354

Nov 10, 2017 by Todd Campbell

Ionis Pharmaceuticals' Earnings Results Fuel Volatility

A confusing quarter and pipeline uncertainty have investors scratching their heads over what to do with this biotech stock.

IF_healthcare

Nov 9, 2017 by Todd Campbell

Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?

The much-maligned drugmaker is making progress, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning a key FDA approval.

VISION GettyImages-674650502

Nov 8, 2017 by Todd Campbell

This Gene Therapy Can Restore Vision, but Will It Break the Bank?

If Spark Therapeutics' game-changing new treatment Luxturna gets FDA approval in January, it may launch with an eye-popping price tag.

stock chart climbing GettyImages-511197926

Nov 8, 2017 by Todd Campbell

Why Nektar Therapeutics Shares Are Soaring 13% Higher

Third-quarter financial results that impressed kindled investor enthusiasm.

young_woman_question_marks_GettyImages-476562658

Nov 8, 2017 by Todd Campbell

Is the Worst Behind Valeant Pharmaceuticals' Stock?

Third-quarter financials ignited a sharp rally in the company's stock, but there are a couple of lingering question marks every investor ought to know about.

man with money falling getty-images-happy-retiree-raining-money_large

Nov 8, 2017 by Todd Campbell

I'm Up 370% on This Under-the-Radar Stock, and I'm Not Selling

It may only be in the early innings for this fast-growing healthcare stock.

money in a pill getty

Nov 8, 2017 by Todd Campbell

Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise

The company's winning new customers, but that didn't help its third-quarter financials.

ACA GettyImages-507157076

Nov 7, 2017 by Todd Campbell

The Insurer That's Crushing It in Obamacare

Other insurers may be retreating from the Affordable Care Act marketplaces, but this insurer's not only making money on the exchanges -- it's also planning to sell plans in more states next year.

earnings GettyImages-579765290

Nov 6, 2017 by Todd Campbell

3 High Growth Stocks You Could Regret Not Buying

Fast-growing companies can provide extra performance over time, and that could make adding these top stocks to portfolios smart.

mzor surgeon_performing_surgery_spinal_implant

Nov 6, 2017 by Todd Campbell

This Growing Robotics Company Is a Hit With Surgeons (Hint: It's not Intuitive Surgical)

It may be easier than ever for Medtronic to sell the spine surgery robots made by this tiny upstart.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services